Xbiotech inc. (XBIT)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenue

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gross margin

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

20,718

24,090

18,596

18,003

17,259

15,725

16,789

17,779

21,229

26,424

34,201

39,045

42,862

42,486

39,215

39,172

32,338

31,310

25,289

19,899

18,763

14,329

0

0

0

General and administrative

9,888

7,143

5,434

5,031

5,390

5,269

5,604

6,092

6,709

7,635

8,792

9,814

9,924

10,277

9,177

7,575

7,215

6,200

6,540

8,096

6,716

7,449

0

0

0

Total operating expenses

30,606

31,233

24,030

23,034

22,649

20,994

22,393

23,871

27,938

34,059

42,993

48,859

52,786

52,763

48,392

46,747

39,553

37,510

31,829

27,995

25,479

21,778

0

0

0

Loss from operations

-27,599

-31,233

-24,030

-23,034

-22,649

-20,994

-22,393

-23,871

-27,938

-34,059

-42,993

-48,859

-52,786

-52,763

-82,862

-59,589

-39,553

-37,510

2,641

-15,153

-25,479

-21,778

0

0

0

Other income (loss):
Interest income

2,384

564

508

358

414

400

339

362

369

354

335

212

98

49

0

0

0

-

-

-

-

-

-

-

-

Other income

-

10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign exchange loss

-835

-888

-469

-216

-711

-548

-222

79

913

555

359

69

-379

-47

119

222

-94

6

-118

-179

143

53

0

0

0

Total other income (loss)

751,550

749,686

53

156

-284

-144

117

441

1,282

909

694

281

-281

2

140

243

-73

27

-117

-178

144

54

0

0

0

Loss before income taxes

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for income taxes

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

674,479

668,629

-23,977

-22,878

-22,933

-21,138

-22,276

-23,430

-26,656

-33,150

-42,299

-48,578

-53,067

-52,761

-48,252

-46,504

-39,626

-37,483

-31,946

-28,173

-25,335

-21,724

0

0

0

Net loss per share—basic and diluted (in dollars per share)

0.00

-

-0.15

-0.16

-0.16

-

-0.14

-0.16

-0.11

-

-0.18

-0.26

-0.32

-0.51

-0.38

-0.42

-0.32

-0.38

-0.33

-0.22

-0.29

-0.26

-0.29

-0.16

-0.19

Weighted-average number of common shares—basic and diluted (in shares)

36,169

-

41,019

37,519

35,977

-

35,819

35,819

35,447

-

35,423

35,320

33,291

32,506

32,436

32,378

32,292

32,227

32,050

31,287

27,641

25,233

24,116

23,749

23,550

Manufacturing Revenue [Member]
Revenue

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical Trial Service Revenue [Member]
Revenue

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-